Suppr超能文献

相似文献

1
Skp2B attenuates p53 function by inhibiting prohibitin.
EMBO Rep. 2010 Mar;11(3):220-5. doi: 10.1038/embor.2010.2. Epub 2010 Feb 5.
3
Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation.
Cell Cycle. 2016 May 18;15(10):1344-51. doi: 10.1080/15384101.2016.1160986. Epub 2016 Apr 25.
4
Skp2B stimulates mammary gland development by inhibiting REA, the repressor of the estrogen receptor.
Mol Cell Biol. 2007 Nov;27(21):7615-22. doi: 10.1128/MCB.01239-07. Epub 2007 Sep 4.
5
Skp2 suppresses p53-dependent apoptosis by inhibiting p300.
Mol Cell. 2008 Feb 1;29(2):217-31. doi: 10.1016/j.molcel.2007.11.036.
6
Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer.
Oncogene. 2005 May 12;24(21):3448-58. doi: 10.1038/sj.onc.1208328.
7
Skp2 and Skp2B team up against Rb and p53.
Cell Div. 2011 Jan 21;6(1):1. doi: 10.1186/1747-1028-6-1.
8
Skp2 Inhibitors: Novel Anticancer Strategies.
Curr Med Chem. 2016;23(22):2363-79. doi: 10.2174/0929867323666160510122624.
9
A Chemical Inhibitor of the Skp2/p300 Interaction that Promotes p53-Mediated Apoptosis.
Angew Chem Int Ed Engl. 2016 Jan 11;55(2):602-6. doi: 10.1002/anie.201508716. Epub 2015 Nov 23.

引用本文的文献

3
Viral strategies for circumventing p53: the case of severe acute respiratory syndrome coronavirus.
Curr Opin Oncol. 2021 Mar 1;33(2):149-158. doi: 10.1097/CCO.0000000000000713.
4
Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases.
Cell Mol Life Sci. 2020 Sep;77(18):3525-3546. doi: 10.1007/s00018-020-03475-1. Epub 2020 Feb 15.
5
Prohibitin promotes androgen receptor activation in ER-positive breast cancer.
Cell Cycle. 2017 Apr 18;16(8):776-784. doi: 10.1080/15384101.2017.1295193. Epub 2017 Mar 8.
6
Recent advances in SCF ubiquitin ligase complex: Clinical implications.
Biochim Biophys Acta. 2016 Aug;1866(1):12-22. doi: 10.1016/j.bbcan.2016.05.001. Epub 2016 May 5.
7
Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation.
Cell Cycle. 2016 May 18;15(10):1344-51. doi: 10.1080/15384101.2016.1160986. Epub 2016 Apr 25.
9
Prohibitin ligands in cell death and survival: mode of action and therapeutic potential.
Chem Biol. 2013 Mar 21;20(3):316-31. doi: 10.1016/j.chembiol.2013.02.006.
10
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.
Front Oncol. 2012 Nov 28;2:173. doi: 10.3389/fonc.2012.00173. eCollection 2012.

本文引用的文献

1
Transcriptional responses to estrogen and progesterone in mammary gland identify networks regulating p53 activity.
Endocrinology. 2008 Oct;149(10):4809-20. doi: 10.1210/en.2008-0035. Epub 2008 Jun 12.
2
Skp2 suppresses p53-dependent apoptosis by inhibiting p300.
Mol Cell. 2008 Feb 1;29(2):217-31. doi: 10.1016/j.molcel.2007.11.036.
3
Skp2B stimulates mammary gland development by inhibiting REA, the repressor of the estrogen receptor.
Mol Cell Biol. 2007 Nov;27(21):7615-22. doi: 10.1128/MCB.01239-07. Epub 2007 Sep 4.
4
Prohibitin: a potential target for new therapeutics.
Trends Mol Med. 2005 Apr;11(4):192-7. doi: 10.1016/j.molmed.2005.02.004.
5
Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer.
Oncogene. 2005 May 12;24(21):3448-58. doi: 10.1038/sj.onc.1208328.
6
Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling.
J Biol Chem. 2003 Nov 28;278(48):47853-61. doi: 10.1074/jbc.M305171200. Epub 2003 Sep 18.
7
P53+/- hemizygous knockout mouse: overview of available data.
Toxicol Pathol. 2001;29 Suppl:30-50. doi: 10.1080/019262301753178465.
8
p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis.
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12379-84. doi: 10.1073/pnas.221459098. Epub 2001 Oct 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验